The PRIMA system, approved in Europe in July, combines a retinal implant with camera‑equipped eyeglasses to restore vision in patients with geographic atrophy, an advanced form of age‑related macular degeneration that affects more than 5 million people worldwide. After training sessions, more than 80 % of recipients were able to read, solve crosswords, and use their phones. The technology was developed by Science Corporation and leverages the fact that geographic atrophy destroys only photoreceptors while leaving other retinal circuitry intact.
Key Takeaways
- PRIMA received European approval in July and is awaiting FDA clearance in the United States.
- Clinical training enabled over 80 % of users to read, complete crosswords, and operate smartphones.
- The system uses a 5‑megapixel camera running at 30 fps to capture real‑time video.
- The retinal implant contains 378 pixels, each powered by photovoltaic cells that eliminate the need for a battery.
| Metric | Value | Why it matters |
|---|---|---|
| Approved Region | Europe (July) | First regulatory milestone for the device. |
| Patient Population | >5 million with geographic atrophy | Large unmet medical need. |
| Implant Pixels | 378 | High‑resolution stimulation of retinal circuitry. |
| Infrared Wavelength | 880 nm | Invisible to the eye, safe for ocular exposure. |
| Camera Resolution | 5 megapixels, 30 fps | Real‑time video feed for visual reconstruction. |
What Is the PRIMA System?
The PRIMA system is a combined hardware solution that includes a retinal implant surgically placed in the back of the eye and a pair of eyeglasses equipped with a miniature front‑facing camera. The glasses capture the visual scene, which is then processed and relayed back to the implant as infrared light pulses. The implant stimulates the remaining healthy retinal neurons, allowing the brain to reconstruct a visual image.
How Does the Technology Work?
Geographic atrophy selectively destroys photoreceptor cells while preserving downstream retinal circuitry. PRIMA’s implant mimics the function of the lost photoreceptors by delivering electrical stimulation directly to bipolar and ganglion cells. Each of the 378 implant pixels contains an electrode and two photovoltaic cells. The photovoltaic cells convert incoming near‑infrared light (880 nm) into electrical current, which both powers the implant and drives the stimulation. This dual role eliminates the need for an external battery.
The eyeglasses house a 5‑megapixel camera that records at 30 frames per second, a resolution comparable to standard television. The raw video stream travels via a fiber‑optic cable to a handheld processor. The processor translates the visual data into a pattern of infrared light pulses that are projected back onto the eye by a laser projector mounted on the glasses. Users can adjust contrast, brightness, and zoom through physical buttons on the device.
“We’re leveraging all of the body’s own natural functions to process and transmit the information.” – Frank Brodie, ophthalmologist at the University of California, San Francisco and Science Corp.’s chief medical officer for ophthalmology
Clinical Outcomes and Training
In clinical trials, participants with advanced geographic atrophy underwent a series of training sessions to learn how to interpret the visual input generated by the PRIMA system. Following this training, more than 80 % of recipients reported the ability to read text, solve crossword puzzles, and use smartphones. These functional gains demonstrate that the device can translate retinal stimulation into usable vision for everyday tasks.
Development and Regulatory Status
Science Corporation, a California‑based company, led the development of the PRIMA system. The device received approval from European regulators in July and is currently awaiting clearance from the U.S. Food and Drug Administration. The European approval marks a significant milestone, indicating that the system has met safety and efficacy standards in a large population of patients with geographic atrophy.
Future Potential and Limitations
While the PRIMA system offers a tangible solution for restoring vision in patients with geographic atrophy, its applicability is limited to cases where retinal circuitry beyond photoreceptors remains intact. The technology does not address other forms of macular degeneration that damage deeper retinal layers. Additionally, the system requires surgical implantation and a learning curve for users to adapt to the new visual input. Future research may explore expanding the technology to other retinal disorders or integrating advanced image‑processing algorithms to enhance visual fidelity.
Why It Matters
Geographic atrophy currently has no approved treatment that can restore vision. The PRIMA system’s ability to convert captured images into electrical stimulation that the brain can interpret represents a paradigm shift in retinal prosthetics. By harnessing the body’s existing neural pathways and eliminating the need for external power sources, the device offers a more seamless and potentially long‑term solution for millions of patients worldwide.
Frequently Asked Questions
What conditions does the PRIMA system treat?
The system is designed for patients with geographic atrophy, an advanced form of age‑related macular degeneration that destroys photoreceptor cells while leaving other retinal circuitry intact.
How many patients have benefited from the PRIMA system?
In clinical trials, more than 80 % of recipients were able to read, solve crosswords, and use smartphones after completing training sessions.
What is the approval status of the PRIMA system?
The device received regulatory approval in Europe in July and is awaiting clearance from the U.S. Food and Drug Administration.
How does the implant power itself?
Each pixel contains photovoltaic cells that convert near‑infrared light into electrical current, eliminating the need for a battery.
What is the role of the eyeglasses in the system?
The glasses house a 5‑megapixel camera that captures real‑time video, a processor that translates the video into infrared pulses, and a laser projector that sends those pulses to the retinal implant.
Bottom Line
The PRIMA system represents a significant advancement for patients with geographic atrophy, offering a surgical solution that restores functional vision without relying on external power. With European approval already secured and U.S. clearance pending, the technology is poised to fill a critical gap in the treatment of advanced age‑related macular degeneration. Its success will hinge on continued clinical validation, regulatory approval, and the ability to scale production to meet the needs of the >5 million affected worldwide.
Reporting based on: original source.
Comments
Post a Comment